NCT01844700View on ClinicalTrials.gov

1/2-MC4R Genotype and Pediatric Antipsychotic Drug- Induced Weight Gain

PHASE4TerminatedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

July 31, 2013

Primary Completion Date

April 30, 2014

Study Completion Date

April 30, 2014

Conditions
High Risk MC4R GenotypeLow Risk MC4R GenotypeOne Week or Less Antipsychotic Lifetime Exposure
Interventions
DRUG

Ziprasidone

random assignment to ZIP (20-160mg/d, bid dosing)

DRUG

aripiprazole, quetiapine, or risperidone

random assignement to Usual Care antipsychotic UC antipsychotic (aripiprazole 2-30mg/d, quetiapine 25-800mg/d or risperidone 0.1-8mg/d)

Trial Locations (1)

11004

Zucker Hillside Hospital, Psychiatry Research, Glen Oaks

Sponsors

Lead Sponsor

Northwell Health
All Listed Sponsors
lead

Northwell Health

OTHER